Related Experiment Video
Updated: May 15, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges
Francesco Massari1, Francesca Maines, Alessandra Modena
1Medical Oncology, G.B. Rossi Academic Hospital, University of Verona, Piazzale L.A. Scuro 10, Verona, Italy.
Abstract:
The rapid approval of several novel agents has given prostate cancer patients and their treating physicians many new and effective therapeutic options. Four new medical therapies were recently approved on the basis of prolonged overall survival in castration-resistant prostate cancer (CRPC) patients: sipuleucel-T, cabazitaxel, abiraterone acetate and MDV3100. Additionally, there are several other promising prostate cancer agents in late-stage development, including PROSTVAC-VF, orteronel and radium-223 chloride, each with a novel mechanism of action. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents. In this review, we discuss the recent progress in understanding the biology of this disease and examining the development of a variety of new agents with promising activity and a favorable toxicity profile, that have been investigated in the setting of hormonal, cytotoxic, immune and targeted therapy. In this new therapeutic setting of CRPC, clinicians will have an opportunity to balance benefits and harms of these new agents in an individual context.
Insights
Novel therapies offer new hope for castration-resistant prostate cancer (CRPC) patients. Research is ongoing to determine the best ways to use these advanced treatments, including sipuleucel-T and abiraterone acetate, for improved survival.
Area of Science:
- Oncology
- Medical Therapeutics
- Prostate Cancer Research
Background:
- Castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
- Recent advancements have introduced novel therapeutic agents for CRPC management.
Purpose of the Study:
- To review recent progress in understanding CRPC biology.
- To examine the development of new agents for CRPC treatment.
- To discuss the evolving treatment paradigm for CRPC.
Main Methods:
- Review of recently approved and late-stage investigational agents for CRPC.
- Analysis of novel mechanisms of action including hormonal, cytotoxic, immune, and targeted therapies.
- Discussion of clinical trial outcomes regarding overall survival and toxicity profiles.
Main Results:
- Four novel therapies (sipuleucel-T, cabazitaxel, abiraterone acetate, MDV3100) approved based on prolonged overall survival.
- Several promising agents (PROSTVAC-VF, orteronel, radium-223 chloride) in late-stage development with novel mechanisms.
- New agents demonstrate promising activity and favorable toxicity profiles.
Conclusions:
- The therapeutic landscape for CRPC is rapidly evolving with new options.
- Optimal sequencing and combination of these agents require further investigation.
- Clinicians must balance benefits and harms of new CRPC therapies in individual patients.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers